Department of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Physiology, School of Basic Medicine Science, Central South University, Changsha, Hunan, China; National Experimental Teaching Demonstration Center for Medical Function, China.
Department of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Xiangya Hospital, Central South University, Changsha, Hunan, China; Basic and Clinical Research Laboratory of Major Respiratory Diseases, Central South University, Changsha, Hunan, China; National Experimental Teaching Demonstration Center for Medical Function, China.
Eur J Pharmacol. 2024 Oct 5;980:176846. doi: 10.1016/j.ejphar.2024.176846. Epub 2024 Jul 25.
Chronic lung disease is the third leading cause of death globally, imposing huge burden of death, disability and healthcare costs. However, traditional pharmacotherapy has relatively limited effects in improving the cure rate and reducing the mortality of chronic lung disease. Thus, new treatments are urgently needed for the prevention and treatment of chronic lung disease. It is particularly noteworthy that, multiple aging-related phenotypes were involved in the occurrence and development of chronic lung disease, such as blocked proliferation, telomere attrition, mitochondrial dysfunction, epigenetic alterations, altered nutrient perception, stem cell exhaustion, chronic inflammation, etc. Consequently, senescent cells induce a series of pathological changes in the lung, such as immune dysfunction, airway remodeling, oxidative stress and regenerative dysfunction, which is a critical issue that needs special attention in chronic lung diseases. Therefore, anti-aging interventions may bring new insights into the treatment of chronic lung diseases. In this review, we elaborate the involvement of aging in chronic lung disease and further discuss the application and prospects of anti-aging therapy.
慢性肺部疾病是全球第三大致死原因，给死亡、残疾和医疗保健成本带来了巨大负担。然而，传统的药物治疗在提高慢性肺部疾病的治愈率和降低死亡率方面效果相对有限。因此，迫切需要新的治疗方法来预防和治疗慢性肺部疾病。特别值得注意的是，多种与衰老相关的表型参与了慢性肺部疾病的发生和发展，如增殖受阻、端粒磨损、线粒体功能障碍、表观遗传改变、营养感知改变、干细胞耗竭、慢性炎症等。因此，衰老细胞会在肺部引起一系列病理变化，如免疫功能障碍、气道重塑、氧化应激和再生功能障碍，这是慢性肺部疾病中需要特别关注的一个关键问题。因此，抗衰老干预措施可能为慢性肺部疾病的治疗带来新的思路。在这篇综述中，我们详细阐述了衰老在慢性肺部疾病中的作用，并进一步讨论了抗衰老治疗的应用和前景。
